UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Rivian Hints at New R2 Variants as Production Ramps Up Ahead of 2027 Launch 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
JD Sports Backs Nike CEO Elliott Hill Amid Brand Turnaround Efforts 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
SEATTLE, May 02, 2018 -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the company’s management is scheduled to present at the Bank of America Merrill Lynch 2018 Heath Care Conference.
Brad Gray, president and chief executive officer, is scheduled to present on Tuesday, May 15, 2018 at 10:55am PT. Interested parties can access the live webcast with accompanying slides from the investor section of the company’s website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 60 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.
For more information, please visit www.nanostring.com.
NanoString, NanoString Technologies, the NanoString logo, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.
Contact:
Doug Farrell
Vice President, Investor Relations & Corporate Communications
[email protected]
Phone: 206-602-1768
